Please login to the form below

Not currently logged in
Email:
Password:

enasidenib

This page shows the latest enasidenib news and features for those working in and with pharma, biotech and healthcare.

Servier to acquire Agios’ oncology business in $1.8bn deal

Servier to acquire Agios’ oncology business in $1.8bn deal

In addition, Servier will also gain the co-commercialisation responsibilities for Bristol Myers Squibb-partnered Idhifa (enasidenib), which is also indicated for AML.

Latest news

More from news
Approximately 1 fully matching, plus 5 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Say Communications

Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...

Latest intelligence

How can we strike the right balance between familiarity and innovation when it comes to data presentation?
Following our webinar in March, Getting MedComms right: navigating the age of the amateur expert, we’re taking the time to respond to questions we were unable to answer during the...
Deep 6 AI: the smart software breathing new life into clinical trials
Fishawack Health interviews Wout Brusselaers, the Deep 6 AI CEO using artificial intelligence to solve one of the greatest barriers stagnating healthcare innovation—clinical trial recruitment and retention....
COVID-proof: How Teams are Creating Launch Intensity thru Adversity
Now that the game has changed, how are marketers shifting their launch behaviour? We've identified 5 common observations from effective teams....